Services on Demand
Journal
Article
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Revista mexicana de angiología
On-line version ISSN 2696-130XPrint version ISSN 0377-4740
Abstract
OLIVARES-GARCIA, Jorge D.; ROMAN-HERNANDEZ, Rigoberto and MERAZ-MARTINEZ, Manuel. Effect of combined treatment of statins and evolocumab in patients with peripheral arterial disease. Rev. mex. angiol. [online]. 2023, vol.51, n.3, pp.85-92. Epub Sep 25, 2023. ISSN 2696-130X. https://doi.org/10.24875/rma.23000019.
Background:
Atherosclerosis is characterized by the deposition of cholesterol and hardening of the endothelium. Evolocumab is a monoclonal antibody that inhibits PCSK9 and stabilizes the atheromatous plaque.
Objective:
To evaluate the effect of evolocumab and statins on peripheral arterial disease (PAD).
Methods:
A prospective observational cohort study that included 303 patients with PAD in claudication treated with statins and evolocumab and evolocumab, compared to monotherapy with statins, during a period of six months, from July 2021 to July 2022. Baseline and final measurements of serum LDL levels, the percentage of arterial stenosis by arterial Doppler ultrasound, the ankle-brachial index and claudication were obtained. Kruskal-Wallis and Mann-Whitney U tests were performed.
Results:
The combined treatment reduced the percentage of arterial stenosis in the femoral, tibial, and peroneal branches (p < 0.05) as well as in LDL levels (p < 0.0001) and reported 50% less claudication.
Conclusions:
In our study, the treatment with evolocumab and statins decreased arterial stenosis and claudication in patients with PAD.
Keywords : Peripheral artery disease; Atherosclerosis; Claudication; PCSK9 inhibitors; Evolocumab.
